Guillain–Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: A case report and review of the literature-Reference-Cited by-同舟云学术

Guillain–Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: A case report and review of the literature

Published:2010-07 Issue:7 Volume:34 Page:e154-e156
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Abbi Kamal K.S.,Rizvi Syed M.,Sivik Jeffrey,Thyagarajan Subramanian,Loughran Thomas,Drabick Joseph J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference22 articles.

1. Schipperus Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in The Netherlands;Laros-van Gorkom;Neth J Med,2007

2. Autoimmune thyroid Disease after renal transplantation using depletional induction with alemtuzumab;Kirk;Am J Transplant,2006

3. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used;Loh;Blood,2007

4. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients;Elimelakh;Haematologica,2007

5. Levels of expression of CD52 in normal and leukemic Band T cells: correlation with in vivo therapeutic responses to Campath-1H;Ginaldi;Leuk Res,1998

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome;Neurotherapeutics;2022-04

2. Toxic Neuropathies;Acquired Neuromuscular Disorders;2022

3. Safety of Newer Disease Modifying Therapies in Multiple Sclerosis;Vaccines;2020-12-26

4. Biological Drugs in Guillain-Barré Syndrome: An Update;Current Neuropharmacology;2017-08-28

5. Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation;Clinical Pharmacokinetics;2017-07-01